TGFB1 and neoplasm: The potential of blocking ECM remodeling by DDR1 antagonists, anti-TGF-β antibodies, and MMP inhibitors (like batimastat) is being studied as a treatment option for tumor metastases (Nam et al., 2008; Liu and Khalil, 2017; Winer et al., 2018; Yang et al., 2020; Wu et al., 2024).